Heparin-induced thrombocytopenia: Yet another treatment paradox?

Thrombosis and Haemostasis

Volumn 85, Issue 6, 2001, Pages 947-949

  Warkentin, T E ^a  

^a HAMILTON REGIONAL LABORATORY MEDICINE PROGRAM   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARGATROBAN; DANAPAROID; HEPARIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN;

ANTICOAGULANT THERAPY; BLEEDING; CLINICAL FEATURE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DOSE CALCULATION; DRUG ACTIVITY; DRUG BINDING; DRUG EFFICACY; DRUG INDUCED DISEASE; HUMAN; NOTE; PRIORITY JOURNAL; PROPHYLAXIS; THROMBOCYTOPENIA; THROMBOSIS;

EID: 0034976837     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615945     Document Type: Note

References (28)

1. Clinical picture of heparin-induced thrombocytopenia
2. Frequency of heparin-induced thrombocytopenia
3. A 14-year study of heparin-induced thrombocytopenia
4. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin
5. Heparin-induced thrombocytopenia (HIT) in orthopedic patients - A prospective cohort trial comparing UFH and LMWH
6. Treatment of heparin-induced thrombocytopenia: An overview
7. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety
8. The use of low-molecular-weight heparins in heparin-induced thrombocytopenia (HIT): A cohort study
9. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia
10. Multicentric warfarin-induced skin necrosis complicating heparin-induced thrombocytopenia
11. Heparin-induced thrombocytopenia with thromboembolic complications: Meta-analysis of two prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range
12. The appropriate use of platelets: An update from the Edinburgh Consensus Conference
13. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia
14. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia
15. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia. A prospective study
16. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia
17. Danaparoid for the treatment of heparin-induced thrombocytopenia
18. Newer strategies for the treatment of heparin-induced thrombocytopenia
19. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial
20. Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with orgaran (Org 10172)
21. Argatroban for treatment of heparin-induced thrombocytopenia
22. Lower limb veins should be systematically explored in patients with isolated heparin-induced thrombocytopenia
23. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia
24. Generation of platelet-derived microparticles and procoagulant activity by heparin-induced thrombocytopenia IgG/serum and other IgG platelet agonists: A comparison with standard platelet agonists
25. Morphological analysis of microparticle generation in heparin-induced thrombocytopenia
26. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells
27. Heparin-associated thrombocytopenia: Isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen
28. Induction of monocyte tissue factor expression by antibodies to platelet factor 4 developed in heparin-induced thrombocytopenia